Nebivolol Aurovitas (Nebivolol Hydrochloride)

Nebivolol is a β1‑selective blocker used in cardiovascular conditions.

• Hypertension: lowers blood pressure and reduces cardiovascular risk.
• Heart failure: improves left ventricular function and decreases hospitalization when indicated.
• High‑risk cardiovascular patients: provides additional blood‑pressure control and may improve endothelial function.

• Nebivolol selectively antagonizes β1‑adrenergic receptors in cardiac tissue, reducing heart rate and myocardial contractility, which lowers cardiac output and blood pressure. Concurrently, it stimulates endothelial nitric‑oxide synthase, enhancing nitric‑oxide release and causing vasodilation, further contributing to its antihypertensive effect.

Nebivolol may cause adverse reactions, which vary in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often occurring early in therapy.
• Dizziness: sensation of light‑headedness, especially when standing quickly.
• Fatigue: generalized tiredness that may improve with continued use.
• Nasal congestion: feeling of blocked nose without infection.

Serious or Rare Side Effects

• Bradycardia: abnormally slow heart rate requiring medical evaluation.
• Severe hypotension: marked drop in blood pressure that can cause fainting.
• Acute heart failure: worsening of cardiac function, presenting with dyspnea or edema.
• Allergic reactions: rash, angioedema, or anaphylaxis requiring immediate care.

When prescribing Nebivolol, clinicians should consider several precautionary measures to ensure safe use.

• Dose adjustment: required in severe renal impairment.
• Monitor blood pressure: avoid symptomatic hypotension.
• Caution in asthma: may exacerbate bronchospasm at higher doses.
• Avoid abrupt discontinuation: risk of rebound hypertension.
• Pregnancy and lactation: safety not established; use only if benefit outweighs risk.
• Store at room temperature: keep in original container, protect from moisture and light.

Nebivolol can interact with other medicines, affecting its efficacy or safety.

Major Interactions (Avoid)

• Concomitant use with non‑selective beta‑blockers.
• Strong CYP2D6 inhibitors such as paroxetine or quinidine.
• Calcium channel blockers that depress AV conduction (verapamil, diltiazem).
• Other antihypertensive agents causing additive hypotension.
• Sympathomimetic drugs (e.g., epinephrine) may reduce therapeutic effect.

Moderate Interactions (Monitor Closely)

• Diuretics may increase risk of hypotension.
• Antidiabetic drugs may mask hypoglycemia symptoms.
• NSAIDs may attenuate antihypertensive response.
• Digoxin levels may be altered, requiring monitoring.
• Lithium clearance may be reduced, increasing toxicity risk.